Contrasting Stoke Therapeutics (STOK) and The Competition

Stoke Therapeutics (NASDAQ:STOK) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Stoke Therapeutics to related businesses based on the strength of its earnings, profitability, valuation, risk, analyst recommendations, institutional ownership and dividends.

Volatility & Risk

Stoke Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Stoke Therapeutics’ rivals have a beta of -1.85, indicating that their average stock price is 285% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stoke Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Stoke Therapeutics	$184.42 million	-$6.89 million	-7.18
Stoke Therapeutics Competitors	$756.66 million	$13.58 million	-19.08

Stoke Therapeutics’ rivals have higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

47.8% of shares of all “Biotechnology” companies are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Stoke Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1	0	10	0	2.82
Stoke Therapeutics Competitors	9869	15283	45611	1598	2.54

Stoke Therapeutics presently has a consensus target price of $44.17, suggesting a potential upside of 63.28%. As a group, “Biotechnology” companies have a potential upside of 122.59%. Given Stoke Therapeutics’ rivals higher possible upside, analysts clearly believe Stoke Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Stoke Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-862.07%	-67.30%	-58.52%
Stoke Therapeutics Competitors	-12,323.33%	-195.38%	-30.39%

Summary

Stoke Therapeutics rivals beat Stoke Therapeutics on 7 of the 13 factors compared.

About Stoke Therapeutics

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.